VERAXA Biotech AG (NASDAQ: VRXA) provided a corporate and pipeline update on Thursday, detailing progress during the first half of 2026 and outlining a strategy focused on advancing its proprietary BiTAC(R) platform while pursuing partnerships for non-core assets. The company reported that its pipeline now includes four BiTAC-based T-cell engager (BiTAC-TCE) programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs, and two non-BiTAC assets available for partnering.
VERAXA said it plans to prioritize investment in its BiTAC portfolio, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028. The company also intends to monetize selected non-BiTAC programs to help finance future development. According to the update, recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company’s differentiated BiTAC platform and its potential to secure strategic collaborations.
“We continue to refine both our pipeline and partnering strategy as we advance our next generation of cancer therapies,” the company stated in the press release. VERAXA executives cited strong industry interest in T-cell engager and ADC technologies, noting that the BiTAC platform’s unique design could offer competitive advantages in solid tumor targeting.
The full press release is available at https://ibn.fm/xTF5q. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL) and is building a pipeline of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company’s newsroom can be accessed at http://ibn.fm/VRXA.
VERAXA’s update underscores the growing interest in bispecific antibodies and ADCs as key modalities in oncology. The company’s strategy to partner non-core assets while focusing internal resources on BiTAC programs reflects a common approach among biotech firms seeking to extend cash runway and maximize value. With VXA-102 expected to reach IND/CTA stage in early 2028, VERAXA is positioning itself for potential clinical data catalysts in the coming years.
Investors and industry observers will be watching for further details on partnering discussions and potential milestone payments that could support the company’s development plans. The announcement did not provide specific financial terms or timelines for any potential collaborations.
